Arctic Bioscience - New long-term financing

01 Apr 2026 10:41 CEST

Arctic Bioscience has secured new long-term financing through a bank loan of NOK
15 million. Together with previously disclosed increase in credit facility of
NOK 8 million from December 2025, the company has increased available liquidity
by a total of NOK 23 million.

The new loan and the increased credit facility are secured through a growth
guarantee from Innovation Norway of NOK 6 million and through guarantees from
various shareholders of a total of NOK 18 million.

Regarding guarantees from shareholders:

Agreements have been entered into with shareholders who have provided guarantees
for the new financing. There will be no guarantee fee to be paid. The guarantors
shall, for the entire term of the loan agreement, have an irrevocable right to
redeem the entire outstanding amount of the loan on behalf of the company by
paying such amount directly to the bank, and to have the resulting claim against
the company converted into shares in the company. The claim is convertible by
the guarantors at any time into freely tradable shares. Conversion price per
share is the lower of 70% x previous 5 trading days VWAP (T+1) from the date the
conversion notice is sent, or maximum conversion price of the lower of NOK 3 or
70% x price-per-share in any equity financing in the period where the guarantee
is valid.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

For more information, please contact:

Christer L. Valderhaug

CEO

Mobile: +47 920 84 601

E-mail: christer@arctic-bioscience.com

Jone R. Slinning

CFO

Mobile: +47 948 75 469

E-mail: jone@arctic-bioscience.com

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing
pharmaceutical and nutraceutical products based on unique bioactive marine
compounds.

The company is developing HRO350 - a novel oral drug candidate. HRO350 is being
developed for treatment of patients with mild-to-moderate psoriasis. This is a
large patient group in need of new effective medicines with beneficial safety
profile.

Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as
well as finished goods under the ROMEGA® brand.

Arctic Bioscience is led by a highly skilled team of talents with diverse and
highly relevant background.

More information:
Access the news on Oslo Bors NewsWeb site